Using Proton Pump Inhibitors is Not Associated with Adverse Outcomes in Patients with Chronic Myeloid Leukemia Treated with Dasatinib

Treatment with the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has markedly improved the outcome of patients with chronic myeloid leukemia (CML). These oral therapies are convenient but raise the concern of potential gastrointestinal malabsorption due to drug-drug interactions. This could compromise the treatment efficacy and result in adverse events (e.g., increasing the concentration of a drug beyond the therapeutic index).1 An important factor influencing TKI absorption is the change in gastric pH.